Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients

This study has been completed.

First Received: November 2, 1999 Last Updated: June 23, 2005 History of Changes

Sponsor:	University of Southern California
Information provided by:	NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:	NCT00002052

Purpose

To compare the effectiveness of standard treatment with parenteral ampicillin and oral amoxicillin compared to initial daily therapy with ceftriaxone followed by 3 times weekly suppressive treatment for salmonella infections in AIDS patients.

Condition	Intervention
HIV Infections Salmonella Infections	Drug: Ceftriaxone sodium Drug: Ampicillin sodium Drug: Amoxicillin trihydrate

Study Type:	Interventional
Study Design:	Treatment, Dose Comparison
Official Title:	Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients

Resource links provided by NLM:

MedlinePlus related topics: AIDS Salmonella Infections

Drug Information available for: Ampicillin sodium Ampicillin Amoxicillin Amoxicillin sodium Amoxicillin trihydrate Ceftriaxone Ceftriaxone Sodium Ampicillin trihydrate

U.S. FDA Resources

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

Type I hypersensitivity to beta-lactam antibiotics.
Not expected to survive 12 weeks.
In a coma or with other central nervous system (CNS) impairment.

Patients with the following are excluded:

Type I hypersensitivity to beta-lactam antibiotics.
Not expected to survive 12 weeks.
In a coma or with other central nervous system (CNS) impairment.

Prior Medication:

Excluded within 48 hours of study entry:

Treatment with an antibiotic active in vitro against Salmonella.

HIV infection, AIDS, or AIDS related complex (ARC).

Salmonella bacteremia or positive stool culture in patient with 3 or more stools per day.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002052

Locations

United States, California
Los Angeles County - USC Med Ctr
Los Angeles, California, United States, 90033

Sponsors and Collaborators

University of Southern California

More Information

No publications provided

Study ID Numbers:	019A
Study First Received:	November 2, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00002052 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:

Salmonella Infections
AIDS-Related Opportunistic Infections
Acquired Immunodeficiency Syndrome
Amoxicillin
Ceftriaxone

Additional relevant MeSH terms:

Bacterial Infections
Anti-Infective Agents
Communicable Diseases
Amoxicillin
RNA Virus Infections
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Immune System Diseases
Enterobacteriaceae Infections
Salmonella Infections
Acquired Immunodeficiency Syndrome
Ampicillin

Ceftriaxone
Infection
Pharmacologic Actions
Immunologic Deficiency Syndromes
Gram-Negative Bacterial Infections
Virus Diseases
Anti-Bacterial Agents
HIV Infections
Therapeutic Uses
Sexually Transmitted Diseases
Lentivirus Infections
Retroviridae Infections

ClinicalTrials.gov processed this record on February 08, 2010